2022-2029 年植入式輸液泵的全球市場

市場概況

全球植入式輸液泵市場預計在 2021 年達到 148.93 億美元，到 2029 年達到 226.45 億美元，在預測期間（2022-2029 年）以 5.7% 的複合年增長率增長。

植入式輸液泵是一種使用細而靈活的導管控制液體和藥物輸送到患者身體特定區域的裝置。醫生可以用它來治療各種疾病，包括肌肉痙攣、糖尿病和慢性疼痛。

市場動態

全球植入式輸液泵市場的增長受到多種因素的推動，例如癌症和糖尿病等慢性病患病率的上升、重大的技術進步以及各種新產品的推出。

慢性病患病率的增加和技術進步的不斷提高預計將推動市場增長。

推動市場增長的主要因素是癌症和糖尿病等慢性病的高患病率，尤其是在老年人中，以及技術的不斷進步。

根據美國國家公共衛生研究所的數據，到 2022 年，癌症將成為全球第二大死因，登記的新病例約為 1,918,030 例。癌症導致全球 609,360 人死亡。此外，根據世衛組織的公告，預計到 2030 年，新病例的數量將增加約 70%。使用最新的植入式輸液泵可以有效地管理各種藥物，並且它們在癌症患者中的使用正在全球範圍內取得進展。

慢性疾病也需要植入式輸液泵。根據加州大學的一項研究，全世界約有 500 萬人患有終末期腎病 (ESRD)。被診斷出患有這種疾病的人數預計將以每年 5-7% 的速度增長。根據國際糖尿病聯合會的數據，全世界約有 4.63 億 20-79 歲的成年人患有糖尿病。預計到 2045 年，這一數字將增加並達到 7 億。

多個組織、團體和研究機構加大力度改進植入式輸液泵和解決安全問題，預計將刺激市場增長。例如，美國食品和藥物管理局 (FDA) 發起了一項改進計劃，以解決植入式輸液泵的安全問題，並鼓勵整個行業開發更安全、更有效的輸液泵。FDA 對植入式輸液泵製造商制定了額外要求，以識別設計缺陷並在安全之前對其進行糾正，要求製造商提交額外的設計和工程作為其上市前提交的一部分。我們已提供信息並決定進行額外測試的設備。FDA 與研究機構、外國監管機構和製造商合作，以促進更安全、更有效的輸液泵的開發。FDA 正在提高醫院工作人員、管理人員和家庭用戶對減輕與使用現有輸液泵相關的風險的認識。

預計患者安全問題和輸液不足將阻礙市場增長。

患者安全因素，特別是圍繞磁共振、頻繁的產品召回、嚴格的法規以及導致嚴重後果的不當注射將阻礙市場的增長。2019 年 12 月發表的一項題為“輸液泵用藥錯誤風險”的研究報告了賓夕法尼亞州 132 家醫院發生的與輸液泵使用和用藥錯誤相關的總共 1,004 起事件。這些事件中有 22% 與高度警告藥物有關。大多數事件是良性的，不會導致嚴重傷害或死亡。

細分分析

活塞式輸液治療領域預計將佔全球植入式輸液泵市場的最大市場份額。

活塞輸液治療領域預計將擁有積極的市場份額，因為它越來越多地融入到體內的藥物輸送中。活塞輸液泵的工作原理類似於汽車中的活塞。隨著活塞的前進，會釋放出微量的藥物。活塞式輸液泵需要專門開發的輸液管。這種管通常包含帶有柱塞的藥筒。這些輸液設備高效且準確。推薦用於易碎液體等產品。

癌症發病率上升是市場增長的主要驅動力。越來越多的公司正在開髮用於輸液的植入式輸液泵。Medtronic、Smiths Medical、Epic Medical 和 Boston Scientific Corporation 被稱為用於藥物輸送的植入式輸液泵的領先製造商。例如，在 2021 年 4 月，B. Brown 與 Online Suite plus 相結合，這是一種提供連接、數據管理、基於雲的應用程序、卓越的處理、續訂靈活性等多種好處的生態系統。我們正在推出創新的輸液泵“Space Plus”。

區域分析

北美在全球植入式輸液泵市場佔有最大的市場份額。

北美是植入式輸液泵的主要市場，占主要收入份額。根據美國衛生與公眾服務部的數據，2010 年美國國家癌症治療支出將達到近 1250 億美元，2020 年將達到 1560 億美元。造成這種情況的原因包括醫療設施的改善、醫療基礎設施的顯著發展、癌症、心血管疾病、終末期腎病的患病率增加以及人口老齡化。

主要參與者的各種技術進步正在擴大市場。例如，Epic Medical Limited 的 SMARTeZ 泵可以通過彈性膜施加的正壓向患者輸送藥物。該泵由兩層矽膠膜構成，以提高流量精度並減少輸液結束時的殘留量。此外，這款彈性輸液泵還提供了一個移動應用程序，以改善患者在不同地點或家中的治療效果。VSCAN 可以評估泵中剩餘的藥物量。SMARTeZ Chemo CS 應用程序可以通過其內置的藥物庫幫助消除人為錯誤並提高患者安全性。

競爭格局

由於多個國際和區域市場，全球數字植入式輸液泵市場競爭激烈。產品多樣化、創收和機會使市場更具競爭力。全球植入式輸液泵市場的主要參與者有 Medtronic PLC、Codman 和 Shurtleff、I-Flow Corp/Halyard Health、Flowonix Medical、Tricumed Medizintechnik、Intera Oncology、Tandem Diabetes Care Inc、Smith's Medical、B. Braun、Terumo Corporation、Ambu Inc.、Medtronic PLC、Concordman 和 Shurtlef。

主要參與者正專注於促進全球市場增長的關鍵戰略，例如合作、收購和產品發布。例如：

• 2022年1月， Smiths Medical被ICU Medical Co., Ltd.從Smiths Group手中收購。流動輸液設備和血管通路是 Smith 的醫療業務，與 ICU 目前的業務相結合，將使我們成為輸液治療的領先供應商。
• 2021 年 4 月，醫療器械製造商 Smiths Medical 將把 Parkview Health 的輸液管理系統——FarmGuard 與其電子健康記錄系統集成，在所有醫院之間實現雙向互操作。這種集成通過自動記錄實現智能泵編程。
• 2020 年 11 月，Ambu Inc. 宣布與 Intalere 就疼痛護理管理解決方案達成協議。Intalere 將收到 Ambu ACtion TM 止痛泵。
• 2020年2月，LTR Medical與Woo Young Medical簽署獨家經銷協議，向澳大利亞市場經銷新一代彈性體注射技術。

值得關注的重點公司

Medtronic PLC

概述 MedtronicPLC，總部位於美國明尼阿波利斯，生產和銷售輸液泵、導管、支架、胰島素筆和血糖監測系統等醫療器械，是一家擁有員工的醫療器械製造商。

產品介紹

Syncromed II 植入式泵。該設備是一種可編程輸液泵，可通過植入導管在鞘內輸送藥物。它用於慢性疼痛管理，可以通過稱為控制工作流程的技術進行控制。這種方法是專門為緩解疼痛和去除全身性阿片類藥物而開發的。

重大發展。2022 年 5 月，醫療保健技術公司 Medtronic plc 宣布其藥物洗脫支架 Onyx Frontier 獲得美國食品和藥物管理局的批准。它是 Resolute DES 系列的最新創新。該支架具有改進的輸送系統，可提供更好的性能和可輸送性。

全球植入式輸液泵市場報告提供了大約 45多個市場數據表、40 多個數字和 180 頁的結構。

目錄

第一章 調查方法和範圍

• 調查方法
• 調查目的和範圍

第二章市場定義和概述

第三章執行摘要

第四章市場動態

• 市場影響因素
  • 促進者
    • 癌症患病率上升
    • 糖尿病和肥胖症的增加
    • 重大技術進步
  • 抑製劑
    • 患者安全和不適當的輸液因素
    • 嚴格的 FDA 規定
  • 商機
  • 影響分析

第五章行業分析

• 波特五力分析
• 供應鏈分析
• 監管分析
• 定價分析
• 未滿足的需求分析

第 6 章 按產品分類

• 活塞輸液泵
• 蠕變輸液泵

第 7 章 按申請

• 癌症治療
• 痙攣性疾病治療
• 疼痛管理
  • 非惡性腫瘤疼痛
  • 惡性腫瘤
• 糖尿病

第 8 章最終用戶

• 醫院
• 專科診所
• 門診手術中心

第9章按地區

• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 意大利
  • 西班牙
  • 歐洲其他地區
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 亞太其他地區
• 中東/非洲

第 10 章 競爭格局

• 競爭情景
• 競爭對手戰略分析
• 產品組合比較分析
• 市場/份額分析
• 併購分析

第十一章公司簡介

• Medtronic PLC
  • 公司簡介
  • 產品組合和描述
  • 主要亮點
  • 財務概覽
• Codman and Shurtleff
• I-Flow Corp/Halyard Health
• Flowonix Medical
• Tricumed Medizintechnik
• Intera Oncology
• Tandem Diabetes Care Inc.
• Boston Scientific Corporation
• Terumo Corporation
• B. Braun（*LIST NOT EXHAUSTIVE）

第 12 章 數據管理

Market Overview

The Global Implantable Infusion Pumps Market was valued at US$ 14,893 million in 2021 and is estimated to reach US$ 22,645 million by 2029, growing at a CAGR of 5.7 during the forecast period (2022-2029).

The implantable infusion pump is a device used to deliver fluids and medications into a particular part of a patient's body with the help of a flexible and thin catheter in a controlled manner. Healthcare practitioners may use them for various treatments such as muscle spasticity, diabetes and chronic pain.

Market Dynamics

The global implantable infusion pumps market growth is driven by several factors, including the rising prevalence of chronic diseases such as cancer and diabetes, significant technological advancements, and various new product launches.

The increasing prevalence of chronic diseases and rising technological advancements are expected to drive market growth.

The major drivers of increasing market growth are the high prevalence of cancer and chronic diseases such as diabetes, especially in geriatric patients and increasing technological advancements.

According to National Centre for Health, in 2022, cancer was the second leading cause of mortality worldwide, with around 1,918,030 new cases registered 2022. Cancer was responsible for 609,360 deaths all over the world. Moreover, as per WHO, the number of new cases is expected to rise by around 70% by 2030. The administration of a variety of drugs is efficient with the help of the latest implantable infusion pumps, and there is a rise in the adoption of these infusion pumps by cancer patients globally.

Even chronic diseases require implantable infusion pumps; According to a study by the University of California, around 5 million people worldwide are affected by end-stage renal disease (ESRD). The number of patients diagnosed with the disease is expected to increase at a rate of 5-7% annually. According to the International Diabetes Federation, approximately 463 million adults aged 20-79 have diabetes worldwide. This number is expected to increase and reach up to 700 million by 2045.

The rising initiatives of several organizations, associations, and institutes to improve the implantable infusion pump and address safety concerns shall stimulate market growth. For instance, the U.S. Food and Drug Administration (FDA) launched an improvement initiative to address implantable infusion pump safety problems and foster the development of safer, more effective infusion pumps across the industry. The FDA established the additional requirements for implantable infusion pump manufacturers to identify the design deficiencies and correct them before they lead to safety; they provide additional design and engineering information as part of its premarket submissions and conduct additional testing of its devices. The FDA collaborated with institutes, foreign regulatory bodies, and manufacturers to facilitate the development of safer and more effective infusion pumps. The FDA is creating awareness regarding mitigating the risks associated with using existing infusion pumps among hospital staff, administrators, and home users.

Patient safety concern and the improper infusion is expected to hamper the market growth.

The factors concerning patient safety, especially in magnetic resonance surroundings, frequent recalls of products, stringent regulations and improper infusion leading to severe consequences will hamper the market's growth. A study published in Dec 2019, titled "Risk of Medication Errors with Infusion Pumps," reported a total of 1,004 events related to the use of infusion pumps and medication errors that occurred in 132 hospitals in Pennsylvania. 22% of these incidents were related to high-alert medication. Most events were less harmful and didn't lead to serious harm or death.

Segment Analysis

Piston type infusion therapy segment is expected to hold the largest market share in the global implantable infusion pumps market.

The piston-type infusion therapy segment is expected to have a positive market share due to its rising uptake for drug delivery into the body. Piston-driven infusion pumps work similarly to automobile pistons. A minute amount of medicine is released when the piston goes forward. Piston-type pumps need IV tubing specially developed for the device. Generally, such kind of tubes contains a cartridge with a plunger. These devices for intravenous infusion are very efficient as well as accurate. It is highly recommended for products such as fragile fluids.

The increasing cancer incidence is the main factor in the market's growth. There is an increase in companies developing implantable infusion pumps for infusions. Medtronic, Smith's Medical, Epic Medical, and Boston Scientific Corporation are the major players in implantable infusion pumps for drug infusion. For instance, in April 2021, B. Braun launched Space plus, a novel infusion pump combined with Online Suite plus, a kind of ecosystem that provides various benefits, including connectivity, data management, cloud-based applications, excellent therapy, and update flexibility.

Geographical Analysis

North America holds the largest market share in the global implantable infusion pumps market.

North America is the leading market for implantable infusion pumps and accounts for a major revenue share. According to the U.S. Department of Health and Human Services, national expenditures for cancer treatment in the U.S. were nearly US$ 125 billion in 2010 and US$ 156 billion by 2020. The reasons are improved medical facilities, greatly developed healthcare infrastructure, rising cancer, cardiovascular, end-stage renal diseases and the growing geriatric population.

Various technological advancements by key players are increasing the market. For instance, Epic Medical Limited's SMARTeZ Pump allows the medication to be delivered to the patient by positive pressure applied by the elastomeric membrane. It comprises 2 layers of silicone membranes for improving the flow accuracy and reducing the residual volume when the infusion is complete. Moreover, the Mobile Apps are available along with this Elastomeric Infusion Pump to improve patient-user outcomes in alternate sites and at home VSCAN and Chemo C.S. App. VSCAN provides an assessment of the volume of medication remaining in the pump. SMARTeZ Chemo C.S. App helps eliminate human errors and improves patient safety with its onboard drug library.

Competitive Landscape

The global digital implantable infusion pump market is highly competitive with several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Some major key players in the global implantable infusion pumps market are Medtronic PLC, Codman and Shurtleff, I-Flow Corp/Halyard Health, Flowonix Medical, Tricumed Medizintechnik, Intera Oncology, Tandem Diabetes Care Inc., Smith's Medical, B. Braun, Terumo Corporation, Ambu Inc.

The key companies are focusing on key strategies such as collaboration, acquisitions, and product launches which are boosting the growth of the market globally. For instance,

• In Jan 2022, Smiths Medical got acquired by ICU Medical Inc from Smiths Group. Ambulatory infusion devices and vascular access are the medical business of Smiths that, combined with ICU's present business, can make it a leading company in infusion therapy.

• In Apr 2021, Smiths Medical, a medical device company, announced integrating its infusion management system- PharmGuard, by Parkview Health, with their health record system (electronic) to form interoperability that is bi-directional in all the hospitals. This integration will benefit smart pump programming with auto-documentation.

• In Nov 2020, Ambu Inc. announced its contract with Intalere, which will work for pain care management solutions. Intalere is going to receive an Ambu ACTion TM block pain pump.

• In February 2020, LTR Medical entered into an exclusive distribution agreement with Woo Young Medical to distribute their new generation of elastomeric infusion technologies into the Australian market.

Key Companies to Watch

Medtronic PLC:

Overview: Medtronic plc is a medical device company that operates in the U.S. and manufactures and markets medical devices such as infusion pumps, catheters, stents, insulin pens, and glucose monitoring systems, with headquarters in Minneapolis, the U.S. It is operational in around 140 countries, and 90,000 people are employed there.

Product Portfolio:

SynchroMed II Implantable Pumps: This device is a programmable infusion pump that, with an implanted catheter, provides drugs in intrathecal space. It is used for chronic pain management and can be controlled using an approach known as Control workflow. This approach is specially developed for giving pain relief and removing systemic opioids.

Key Developments: In May 2022, Medtronic plc, a healthcare technology company, announced its approval of Onyx Frontier, a drug-eluting stent by the United States Food and Drug Administration. It is the latest innovation in the family of Resolute DES. It is an improved delivery system that provides better performance and deliverability.

The global implantable infusion pumps market report would provide access to an approx. 45+ market data table, 40+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising prevalence of cancer
    • 4.1.1.2. Increasing diabetes and obesity cases
    • 4.1.1.3. Major technological advancements
  • 4.1.2. Restraints
    • 4.1.2.1. Factors concerning patient safety and improper infusion
    • 4.1.2.2. Stringent FDA regulations
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis
• 5.4. Pricing Analysis
• 5.5. Unmet Needs

6. By Product

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Segment
  • 6.1.2. Market Attractiveness Index, By Product Segment
• 6.2. Piston Type Infusion Pumps
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Creeping Type Infusion Pumps

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Segment
  • 7.1.2. Market Attractiveness Index, By Application Segment
• 7.2. Cancer Treatment
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Spasticity Treatment
• 7.4. Pain Management
  • 7.4.1. Non-malignant Pain
  • 7.4.2. Malignant Pain
• 7.5. Diabetes

8. By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Hospitals
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Specialty clinics
• 8.4. Ambulatory Surgical Centres

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. The U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. Australia
    • 9.5.6.5. Rest of Asia Pacific
• 9.6. The Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Competitor Strategy Analysis
• 10.3. Comparative Product Portfolio Analysis
• 10.4. Market Positioning/Share Analysis
• 10.5. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Medtronic PLC
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Codman and Shurtleff
• 11.3. I-Flow Corp/Halyard Health
• 11.4. Flowonix Medical
• 11.5. Tricumed Medizintechnik
• 11.6. Intera Oncology
• 11.7. Tandem Diabetes Care Inc.
• 11.8. Boston Scientific Corporation
• 11.9. Terumo Corporation
• 11.10. B. Braun(*LIST NOT EXHAUSTIVE)

12. DataM Intelligence

• 12.1. Appendix
• 12.2. About Us and Method of Fixation
• 12.3. Contact Us